Mireille Sanders
Chief Operating Officer at PHARMING GROUP N.V.
Net worth: 879 337 $ as of 2024-03-30
Profile
Mireille Sanders is currently the Chief Operations Officer at Pharming Group NV.
Previously, she worked at Janssen Pharmaceuticals, Inc. as the Head-Clinical Supply Chain Strategic from 2016 to 2019.
Ms. Sanders is a graduate of Technische Universiteit Eindhoven.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PHARMING GROUP NV
0.12% | 2024-03-30 | 799,020 ( 0.12% ) | 879 337 $ | 2024-03-30 |
Mireille Sanders active positions
| Companies | Position | Start |
|---|---|---|
| PHARMING GROUP N.V. | Chief Operating Officer | 2020-12-14 |
Former positions of Mireille Sanders
| Companies | Position | End |
|---|---|---|
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | 2018-12-31 |
Training of Mireille Sanders
| Technische Universiteit Eindhoven | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PHARMING GROUP N.V. | Health Technology |
| Private companies | 1 |
|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
- Stock Market
- Insiders
- Mireille Sanders
